Zymeworks (ZYME) Consolidated Net Income (2021 - 2026)
Zymeworks (ZYME) reported Consolidated Net Income of -$44.2 million for Q1 2026, down 95.1% on a YoY basis from -$900.6 million in Q1 2025, and down 7.17% sequentially from -$41.2 million in Q4 2025.
Zymeworks (ZYME) Consolidated Net Income (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Consolidated Net Income data on file, last reported at -$44.2 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 95.1% year-over-year to -$44.2 million; the trailing twelve-month figure through Mar 2026 stood at -$102.7 million (up 9.7% YoY), and the FY2025 full-year result was -$81.1 million, up 33.88% from the prior year.
- Consolidated Net Income declined to -$44.2 million in Q1 2026, from -$41.2 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $309.4 million in Q4 2022 to a low of -$72.6 million in Q1 2022.
- A 5-year average of -$14.3 million and a median of -$29.8 million in 2024 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income surged 890.33% in 2022 and slumped 104.68% in 2023, its largest moves.
- Tracing ZYME's Consolidated Net Income over 5 years: stood at $309.4 million in 2022, then tumbled by 104.68% to -$14.5 million in 2023, then plunged by 62.31% to -$23.5 million in 2024, then tumbled by 75.31% to -$41.2 million in 2025, then declined by 7.17% to -$44.2 million in 2026.
- Business Quant data shows ZYME's Consolidated Net Income at -$44.2 million in Q1 2026, -$41.2 million in Q4 2025, and -$19.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - | -44.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.51 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -28.69 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |